Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)
Others
Ratios

Relay Therapeutics (RLAY) Net Income towards Common Stockholders: 2020-2025

Historic Net Income towards Common Stockholders for Relay Therapeutics (RLAY) over the last 6 years, with Sep 2025 value amounting to -$74.0 million.

  • Relay Therapeutics' Net Income towards Common Stockholders rose 16.02% to -$74.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$296.8 million, marking a year-over-year increase of 14.03%. This contributed to the annual value of -$337.7 million for FY2024, which is 1.24% up from last year.
  • According to the latest figures from Q3 2025, Relay Therapeutics' Net Income towards Common Stockholders is -$74.0 million, which was down 6.08% from -$69.7 million recorded in Q2 2025.
  • Relay Therapeutics' Net Income towards Common Stockholders' 5-year high stood at -$42.2 million during Q1 2021, with a 5-year trough of -$193.4 million in Q2 2021.
  • In the last 3 years, Relay Therapeutics' Net Income towards Common Stockholders had a median value of -$81.4 million in 2024 and averaged -$81.9 million.
  • Examining YoY changes over the last 5 years, Relay Therapeutics' Net Income towards Common Stockholders showed a top increase of 71.56% in 2021 and a maximum decrease of 677.14% in 2021.
  • Quarterly analysis of 5 years shows Relay Therapeutics' Net Income towards Common Stockholders stood at -$67.5 million in 2021, then decreased by 0.03% to -$67.5 million in 2022, then fell by 23.74% to -$83.5 million in 2023, then climbed by 8.97% to -$76.0 million in 2024, then climbed by 16.02% to -$74.0 million in 2025.
  • Its Net Income towards Common Stockholders stands at -$74.0 million for Q3 2025, versus -$69.7 million for Q2 2025 and -$77.1 million for Q1 2025.